BioLife Solutions (BLFS) Stock Forecast & Price Target

Compare

416 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BLFS Analyst Ratings

Strong Buy

8 Buy

0 Hold

0 Sell

Based on 8 analysts giving stock ratings to

BioLife

Solutions

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BLFS Stock 12 Month Forecast

Average Price Target

$32.29

▲(32.39% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for BioLife Solutions in the last 3 months. The average price target is $32.29 with a high forecast of $34.00 and a low forecast of $30.00. The average price target represents a 32.39% change from the last price of $24.39.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"$19","23":"$23","27":"$27","31":"$31","35":"$35"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$34.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,23,27,31,35],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.41,26.07076923076923,26.731538461538463,27.392307692307693,28.053076923076922,28.713846153846156,29.374615384615385,30.035384615384615,30.696153846153848,31.356923076923078,32.01769230769231,32.67846153846154,33.33923076923077,{"y":34,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.41,25.939230769230768,26.46846153846154,26.997692307692308,27.526923076923076,28.056153846153848,28.585384615384616,29.114615384615384,29.643846153846155,30.173076923076923,30.70230769230769,31.231538461538463,31.76076923076923,{"y":32.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.41,25.763076923076923,26.116153846153846,26.46923076923077,26.822307692307692,27.175384615384615,27.52846153846154,27.88153846153846,28.234615384615385,28.587692307692308,28.94076923076923,29.293846153846154,29.646923076923077,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.07,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.27,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.96,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.83,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.6,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.66,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.34,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.13,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.87,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.41,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$34.00

Average Price Target$32.29

Lowest Price Target$30.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yi Chen

H.C. Wainwright

$32

Buy

31.20%

Upside

Reiterated

11/24/25

BioLife Solutions: Strategic Developments and Strong Financial Performance Drive Buy Rating

Jason McCarthy

Maxim Group

$34

Buy

39.40%

Upside

Reiterated

11/11/25

BioLife Solutions: Strategic Focus on High-Margin Cell Processing Tools Drives Strong Financial Performance and Growth Opportunities

Matt Hewitt

Craig-Hallum

―

Buy

―

Reiterated

11/10/25

Analysts Offer Insights on Healthcare Companies: Nkarta (NASDAQ: NKTX), BioLife Solutions (NASDAQ: BLFS) and Cardiff Oncology (NASDAQ: CRDF)

Thomas Flaten

Lake Street

$30→$33

Buy

35.30%

Upside

Reiterated

11/07/25

Lake Street Reaffirms Their Buy Rating on BioLife Solutions (BLFS)

Carl Byrnes

Northland Securities

$31

Buy

27.10%

Upside

Reiterated

11/07/25

Northland Securities Reaffirms Their Buy Rating on BioLife Solutions (BLFS)

Brendan Smith

TD Cowen

$31→$33

Buy

35.30%

Upside

Reiterated

11/06/25

BioLife Solutions: Strong Financial Performance and Strategic Focus Justify Buy Rating

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$30

Buy

23.00%

Upside

Reiterated

10/08/25

BioLife Solutions (BLFS) Receives a Buy from Jefferies

Paul Knight

KeyBanc

$33

Buy

35.30%

Upside

Reiterated

10/03/25

Analysts Offer Insights on Healthcare Companies: BioLife Solutions (NASDAQ: BLFS), Pacific Biosciences (NASDAQ: PACB) and Humana (NYSE: HUM)

Robert Wasserman

Benchmark Co.

$30

Buy

23.00%

Upside

Reiterated

08/11/25

Analysts Conflicted on These Healthcare Names: Green Thumb Industries (Other OTC: GTBIF), Doximity (NYSE: DOCS) and BioLife Solutions (NASDAQ: BLFS)We are maintaining our Buy rating and $30 price target on BLFS shares on the solid 2Q25 results.

Steven Etoch

Stephens

$30

Buy

23.00%

Upside

Initiated

07/21/25

BioLife Solutions resumed with an Overweight at StephensBioLife Solutions resumed with an Overweight at Stephens

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yi Chen

H.C. Wainwright

$32

Buy

31.20%

Upside

Reiterated

11/24/25

BioLife Solutions: Strategic Developments and Strong Financial Performance Drive Buy Rating

Jason McCarthy

Maxim Group

$34

Buy

39.40%

Upside

Reiterated

11/11/25

BioLife Solutions: Strategic Focus on High-Margin Cell Processing Tools Drives Strong Financial Performance and Growth Opportunities

Matt Hewitt

Craig-Hallum

―

Buy

―

Reiterated

11/10/25

Analysts Offer Insights on Healthcare Companies: Nkarta (NASDAQ: NKTX), BioLife Solutions (NASDAQ: BLFS) and Cardiff Oncology (NASDAQ: CRDF)

Thomas Flaten

Lake Street

$30→$33

Buy

35.30%

Upside

Reiterated

11/07/25

Lake Street Reaffirms Their Buy Rating on BioLife Solutions (BLFS)

Carl Byrnes

Northland Securities

$31

Buy

27.10%

Upside

Reiterated

11/07/25

Northland Securities Reaffirms Their Buy Rating on BioLife Solutions (BLFS)

Brendan Smith

TD Cowen

$31→$33

Buy

35.30%

Upside

Reiterated

11/06/25

BioLife Solutions: Strong Financial Performance and Strategic Focus Justify Buy Rating

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$30

Buy

23.00%

Upside

Reiterated

10/08/25

BioLife Solutions (BLFS) Receives a Buy from Jefferies

Paul Knight

KeyBanc

$33

Buy

35.30%

Upside

Reiterated

10/03/25

Analysts Offer Insights on Healthcare Companies: BioLife Solutions (NASDAQ: BLFS), Pacific Biosciences (NASDAQ: PACB) and Humana (NYSE: HUM)

Robert Wasserman

Benchmark Co.

$30

Buy

23.00%

Upside

Reiterated

08/11/25

Steven Etoch

Stephens

$30

Buy

23.00%

Upside

Initiated

07/21/25

BioLife Solutions resumed with an Overweight at StephensBioLife Solutions resumed with an Overweight at Stephens

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioLife Solutions

1 Month

xxx

Success Rate

11/17 ratings generated profit

Average Return

+4.51%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 64.71% of your transactions generating a profit, with an average return of +4.51% per trade.

3 Months

xxx

Success Rate

21/29 ratings generated profit

Average Return

+22.35%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 72.41% of your transactions generating a profit, with an average return of +22.35% per trade.

1 Year

Matt HewittCraig-Hallum

Success Rate

12/17 ratings generated profit

Average Return

+24.25%

reiterated a buy rating last month

Copying Matt Hewitt's trades and holding each position for 1 Year would result in 70.59% of your transactions generating a profit, with an average return of +24.25% per trade.

2 Years

xxx

Success Rate

12/17 ratings generated profit

Average Return

+24.90%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 70.59% of your transactions generating a profit, with an average return of +24.90% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BLFS Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BLFS has received 15 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. BLFS average Analyst price target in the past 3 months is 32.29.

Each month's total comprises the sum of three months' worth of ratings.

BLFS Financial Forecast

BLFS Earnings Forecast

Next quarter’s earnings estimate for BLFS is -$0.01 with a range of -$0.05 to $0.01. The previous quarter’s EPS was $0.01. BLFS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year BLFS has Performed in-line its overall industry.

BLFS Sales Forecast

Next quarter’s sales forecast for BLFS is $24.08M with a range of $23.55M to $24.50M. The previous quarter’s sales results were $28.07M. BLFS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year BLFS has Performed in-line its overall industry.

BLFS Stock Forecast FAQ

What is BLFS’s average 12-month price target, according to analysts?

Based on analyst ratings, BioLife Solutions’s 12-month average price target is 32.29.

What is BLFS’s upside potential, based on the analysts’ average price target?

BioLife Solutions has 32.39% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BLFS a Buy, Sell or Hold?

BioLife Solutions has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.

What is BioLife Solutions’s price target?

The average price target for BioLife Solutions is 32.29. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $34.00 ,the lowest forecast is $30.00. The average price target represents 32.39% Increase from the current price of $24.39.

What do analysts say about BioLife Solutions?

BioLife Solutions’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of BLFS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

BioLife Solutions (BLFS) Stock Forecast & Price Target

BLFS Analyst Ratings

BLFS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BioLife Solutions

BLFS Analyst Recommendation Trends

BLFS Financial Forecast

BLFS Earnings Forecast

BLFS Sales Forecast

BLFS Stock Forecast FAQ

Detailed List of Analyst Forecasts